Are you or someone you know suffering from mild cognitive impairment or mild Dementia due to Parkinson's or Alzheimer's Disease?
This research study is evaluating an investigational drug combination, CST-2032 combined with CST-107 (nadolol), as a possible treatment for cognitive impairment due to Alzheimer’s disease (AD) or Parkinson’s disease (PD) with rapid eye movement (REM) sleep behavior disorder. CuraSen Therapeutics, Inc. is sponsoring this research study.
Alzheimer’s disease is a type of brain disease, just as coronary artery disease is a type of heart disease. It is also a degenerative disease, meaning that it becomes worse with time. Alzheimer’s disease is thought to begin 20 years or more before symptoms arise, with small changes in the brain that are unnoticeable to the person affected.
Only after years of brain changes do individuals experience noticeable symptoms, such as memory loss and language problems. Symptoms occur because nerve cells (neurons) in parts of the brain involved in thinking, learning and memory (cognitive function) have been damaged or destroyed. Individuals typically live with Alzheimer’s symptoms for years. Over time, symptoms tend to increase and start interfering with individuals’ ability to perform everyday activities. At this point, the individual is said to have dementia due to Alzheimer’s disease, or Alzheimer’s dementia. There is currently no cure for Alzheimer’s disease.
Parkinson’s disease is a condition in which cells that produce a chemical called dopamine in parts of the brain stop working properly and are lost over time, leading to damage of those parts of the brain. There are three main symptoms; a resting tremor (shaking), slow movement, and rigidity (muscle stiffness). A person with Parkinson’s disease can also experience a wide range of other physical and psychological symptoms. There is currently no cure for Parkinson’s disease, but existing medications can help control the symptoms.
REM sleep behavior disorder is a condition in which the sufferer physically acts out vivid, often unpleasant dreams with vocal sounds and sudden, violent arm and leg movements during sleep, and is commonly found in people with Parkinson’s Disease. This study seeks to evaluate the safety and efficacy of CST-2032 when dosed with CST-107 compared to placebo in subjects with these conditions.